Bahija Jallal, David Berman, Koustubh Ranadel, and now Mohammed Dar lines up as the latest AstraZeneca/MedImmune executive to jump ship into UK biotech Immunocore. Amid some big changes in R&D at AstraZeneca, Dar comes on board as the T cell receptor biotech’s head of clinical development and chief medical officer, leading work on tebentafusp (IMCgp100) as well as other “key programmes” in Immunocore’s pipeline, including hepatitis B, HIV and autoimmune diseases. Source: Fierce Biotech 7/5/2019